Pharmafile Logo

Johnson & Johnson

The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Johnson & Johnson in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Johnson & Johnson.

Recent articles on PMLiVE featuring Johnson & Johnson

- PMLiVE
Johnson & Johnson announces change in senior leadership role

Tom Cavanaugh has been appointed as Executive Vice President, Worldwide Chairman Innovative Medicine

- PMLiVE
Johnson & Johnson commits $5.5bn to end remaining talc litigation

The resolution comes after plaintiffs were unable to prove that J&J’s talc products caused their ovarian cancer

- PMLiVE
Communiqué Awards 2026: celebrating excellence in healthcare communications

This year’s Awards, held at the Grosvenor House Hotel in London on 2 July, included 32 categories

- PMLiVE
J&J’s Erleada prostate cancer study shows significant reduction in risk of metastasis

Erleada plus hormone therapy significantly improved key short- and long-term clinical outcomes

- PMLiVE
Legend Biotech appoints new group of scientific advisors

The company is focused on CAR-T cell therapy to treat multiple myeloma

- PMLiVE
J&J’s Icotyde approved by US FDA for plaque psoriasis

Plaque psoriasis affects over 125 million people worldwide

- PMLiVE
Johnson & Johnson’s multiple myeloma treatment approved by US FDA

The approval was based on phase 3 data showing survival rates of 83.3% after three years

- PMLiVE
J&J’s nipocalimab gets FDA Fast Track designation for lupus

The autoimmune disease affects approximately three to five million people globally

- PMLiVE
Johnson & Johnson’s Darzalex Faspro regimen receives FDA approval for multiple myeloma

Multiple myeloma has an average five-year survival rate of 59.8% and is currently incurable

- PMLiVE
Johnson & Johnson’s Rybrevant shows positive effects in difficult-to-treat colorectal cancer

Colorectal cancer accounts for around 10% of all cancer cases globally, with an increase in diagnoses in younger people

- PMLiVE
J&J’s Tremfya improves symptoms of psoriatic arthritis including joint damage

Psoriatic arthritis can develop in up to 30% of people with psoriasis

- PMLiVE
J&J receives positive NICE recommendation for multiple myeloma treatment

The treatment is approved for use within the NHS in England and Wales

Data provided by GlobalData

GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.

Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.

To find out more about how our research and insights can help you, please visit  https://www.globaldata.com/who-we-are/why-globaldata/

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links